{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:12:34Z","timestamp":1792001554120,"version":"4.4.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2003,3,26]]},"abstract":"\n Context<\/jats:title>\n Ephedra and ephedrine sometimes are used for weight loss or enhanced athletic performance, but the efficacy and safety of these compounds are uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the efficacy and safety of ephedra and ephedrine used for weight loss and enhanced athletic performance.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n \n We searched 9 databases using the terms\n ephedra<\/jats:italic>\n ,\n ephedrine<\/jats:italic>\n ,\n adverse effect<\/jats:italic>\n ,\n side effect<\/jats:italic>\n ,\n efficacy<\/jats:italic>\n ,\n effective<\/jats:italic>\n , and\n toxic<\/jats:italic>\n . We included unpublished trials and non\u2013English-language documents. Adverse events reported to the US Food and Drug Administration MedWatch program were assessed.\n <\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Eligible studies were controlled trials of ephedra or ephedrine used for weight loss or athletic performance and case reports of adverse events associated with such use. Eligible studies for weight loss were human studies with at least 8 weeks of follow-up; and for athletic performance, those having no minimum follow-up. Eligible case reports documented that ephedra or ephedrine was consumed within 24 hours prior to an adverse event or that ephedrine or an associated product was found in blood or urine, and that other potential causes had been excluded. Of the 530 articles screened, 52 controlled trials and 65 case reports were included in the adverse events analysis. Of more than 18\u00a0000 other case reports screened, 284 underwent detailed review.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction<\/jats:title>\n Two reviewers independently identified trials of efficacy and safety of ephedra and ephedrine on weight loss or athletic performance; disagreements were resolved by consensus. Case reports were reviewed with explicit and implicit methods.<\/jats:p>\n <\/jats:sec>\n \n Data Synthesis<\/jats:title>\n No weight loss trials assessed duration of treatment greater than 6 months. Pooled results for trials comparing placebo with ephedrine (n = 5), ephedrine and caffeine (n = 12), ephedra (n = 1), and ephedra and herbs containing caffeine (n = 4) yielded estimates of weight loss (more than placebo) of 0.6 (95% confidence interval, 0.2-1.0), 1.0 (0.7-1.3), 0.8 (0.4-1.2), and 1.0 (0.6-1.3) kg\/mo, respectively. Sensitivity analyses did not substantially alter the latter 3 results. No trials of ephedra and athletic performance were found; 7 trials of ephedrine were too heterogeneous to synthesize. Safety data from 50 trials yielded estimates of 2.2- to 3.6-fold increases in odds of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations. Data are insufficient to draw conclusions about adverse events occurring at a rate less than 1.0 per thousand. The majority of case reports are insufficiently documented to allow meaningful assessment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Ephedrine and ephedra promote modest short-term weight loss (\u22480.9 kg\/mo more than placebo) in clinical trials. There are no data regarding long-term weight loss, and evidence to support use of ephedra for athletic performance is insufficient. Use of ephedra or ephedrine and caffeine is associated with increased risk of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.289.12.1537","type":"journal-article","created":{"date-parts":[[2003,3,25]],"date-time":"2003-03-25T21:41:23Z","timestamp":1048628483000},"page":"1537","source":"Crossref","is-referenced-by-count":335,"title":["Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance"],"prefix":"10.1001","volume":"289","author":[{"given":"Paul G.","family":"Shekelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally C.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Maglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Mojica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika J.","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Jungvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ref-jrv20107-1","article-title":"Wheeler used supplement.","author":"Abrahamson","year":"2001","journal-title":"Los Angeles Times"},{"key":"ref-jrv20107-2","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJM200012213432502","article-title":"Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.","volume":"343","author":"Haller","year":"2000","journal-title":"N Engl J Med"},{"key":"ref-jrv20107-3","article-title":"Risks of ephedra usage in spotlight.","author":"Carey","year":"2001","journal-title":"Los Angeles Times"},{"key":"ref-jrv20107-5","article-title":"A tug of war in a larger battle: ephedra is now under intense scrutiny.","author":"Marsa","year":"2002","journal-title":"Los Angeles Times"},{"key":"ref-jrv20107-7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref-jrv20107-8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/(ISSN)1097-0258","article-title":"A random-effects regression model for meta-analysis.","volume":"14","author":"Berkey","year":"1995","journal-title":"Stat Med"},{"key":"ref-jrv20107-9","first-page":"S264","article-title":"Effect of ephedrine, caffeine, and aspirin, in combinations of weight loss in obese women [abstract].","volume":"22","author":"Moheb","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref-jrv20107-11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"ref-jrv20107-12","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias.","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref-jrv20107-13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref-jrv20107-16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/0026-0495(92)90304-S","article-title":"The effect of ephedrine\/caffeine mixture on energy expenditure and body composition in obese women.","volume":"41","author":"Astrup","year":"1992","journal-title":"Metabolism"},{"key":"ref-jrv20107-17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/sj.ijo.0802023","article-title":"Herbal ephedra\/caffeine for weight loss.","volume":"26","author":"Boozer","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.ijo.0801539","article-title":"An herbal supplement containing Ma Huang-Guarana for weight loss.","volume":"25","author":"Boozer","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-19","first-page":"329","article-title":"The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ\/day diet.","volume":"18","author":"Buemann","year":"1994","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-20","first-page":"98","article-title":"A pilot study evaluating the effects of an ephedrine and forskolin-based product on body weight and body composition in overweight, healthy women [abstract].","volume":"20","author":"Colker","year":"2001","journal-title":"J Am Coll Nutr"},{"key":"ref-jrv20107-21","first-page":"S73","article-title":"Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity.","volume":"17","author":"Daly","year":"1993","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-22","first-page":"1499","article-title":"Elsinore tablets and ephedrine as slimming agents [in Danish].","volume":"142","author":"Jensen","year":"1980","journal-title":"Ugeskr Laeger"},{"key":"ref-jrv20107-23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0011-393X(00)89034-7","article-title":"Effects of a weight-loss aid in healthy overweight adults.","volume":"61","author":"Kalman","year":"2000","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref-jrv20107-24","first-page":"S264","article-title":"Ephedrine\/caffeine enhances abdominal fat loss in females.","volume":"22","author":"Kettle","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-25","first-page":"1487","article-title":"Ephedrine in the treatment of obesity [in Danish].","volume":"142","author":"Lumholtz","year":"1980","journal-title":"Ugeskr Laeger"},{"key":"ref-jrv20107-26","first-page":"183","article-title":"Ephedrine as an anorectic: the story of the 'Elsinore pill'.","volume":"5","author":"Malchow-Moller","year":"1981","journal-title":"Int J Obes"},{"key":"ref-jrv20107-27","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/sj.ijo.0801433","article-title":"Safety and efficacy of treatment with an ephedrine\/caffeine mixture.","volume":"24","author":"Molnar","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-28","first-page":"93","article-title":"A controlled trial using ephedrine in the treatment of obesity.","volume":"9","author":"Pasquali","year":"1985","journal-title":"Int J Obes"},{"key":"ref-jrv20107-29","first-page":"1258","article-title":"The effect of an ephedrine\/caffeine combination as a supplement to a weight-reducing diet [in Danish].","volume":"154","author":"Quaade","year":"1992","journal-title":"Ugeskr Laeger"},{"key":"ref-jrv20107-30","first-page":"1491","article-title":"Elsinore banting tablets [in Danish].","volume":"142","author":"Roed","year":"1980","journal-title":"Ugeskr Laeger"},{"key":"ref-jrv20107-31","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1038\/sj.ijo.0801175","article-title":"Drug treatment in obese adolescents [abstract].","volume":"24","author":"Van Mil","year":"2000","journal-title":"Int J Obes"},{"key":"ref-jrv20107-32","first-page":"99","article-title":"Comparison of an ephedrine\/caffeine combination and dexfenfluramine in the treatment of obesity.","volume":"18","author":"Breum","year":"1994","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-33","first-page":"2021","article-title":"Aerobic training increases the effect of ephedrine on energy expenditure [in Danish].","volume":"148","author":"Oksbjerg","year":"1986","journal-title":"Ugeskr Laeger"},{"key":"ref-jrv20107-34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s004210050355","article-title":"Effects of caffeine, ephedrine and their combination on time to exhaustion during high-intensity exercise.","volume":"77","author":"Bell","year":"1998","journal-title":"Eur J Appl Physiol Occup Physiol"},{"key":"ref-jrv20107-35","first-page":"325","article-title":"Combined caffeine and ephedrine ingestion improves run times of Canadian Forces Warrior Test.","volume":"70","author":"Bell","year":"1999","journal-title":"Aviat Space Environ Med"},{"key":"ref-jrv20107-36","first-page":"583","article-title":"Thermal regulation in the heat during exercise after caffeine and ephedrine ingestion.","volume":"70","author":"Bell","year":"1999","journal-title":"Aviat Space Environ Med"},{"key":"ref-jrv20107-37","first-page":"415","article-title":"Reducing the dose of combined caffeine and ephedrine preserves the ergogenic effect.","volume":"71","author":"Bell","year":"2000","journal-title":"Aviat Space Environ Med"},{"key":"ref-jrv20107-38","first-page":"471","article-title":"Effects of ingesting caffeine and ephedrine on muscular endurance.","volume":"24","author":"Pasternak","year":"1999","journal-title":"Can J Appl Physiol"},{"key":"ref-jrv20107-39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1097\/00005768-200108000-00024","article-title":"Effect of caffeine and ephedrine ingestion on anaerobic exercise performance.","volume":"33","author":"Bell","year":"2001","journal-title":"Med Sci Sports Exerc"},{"key":"ref-jrv20107-40","first-page":"95","article-title":"The effects of ephedrine on the physiological and psychological responses to submaximal and maximal exercise in man.","volume":"9","author":"Sidney","year":"1977","journal-title":"Med Sci Sports"},{"key":"ref-jrv20107-41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/bmj.314.7073.29","article-title":"Randomised comparison of diets for maintaining obese subjects' weight after major weight loss.","volume":"314","author":"Toubro","year":"1997","journal-title":"BMJ"},{"key":"ref-jrv20107-42","doi-asserted-by":"publisher","first-page":"425S","DOI":"10.1002\/j.1550-8528.1995.tb00209.x","article-title":"Evaluation of drugs for treating obesity.","volume":"3","author":"Bray","year":"1995","journal-title":"Obes Res"},{"key":"ref-jrv20107-43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"ref-jrv20107-44","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2337\/diacare.24.11.1957","article-title":"Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.","volume":"24","author":"Gokcel","year":"2001","journal-title":"Diabetes Care"},{"key":"ref-jrv20107-45","first-page":"505","article-title":"Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.","volume":"50","author":"Smith","year":"2001","journal-title":"J Fam Pract"},{"key":"ref-jrv20107-46","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine.","volume":"286","author":"Wirth","year":"2001","journal-title":"JAMA"},{"key":"ref-jrv20107-47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s002280050433","article-title":"Efficacy and tolerability of orlistat in the treatment of obesity.","volume":"54","author":"Van Gaal","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"ref-jrv20107-48","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.","volume":"69","author":"Hill","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"ref-jrv20107-49","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/sj.ijo.0801443","article-title":"Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.","volume":"24","author":"Karhunen","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-50","first-page":"323","article-title":"Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia [in Serbo-Croatian].","volume":"52","author":"Micic","year":"1999","journal-title":"Med Pregl"},{"key":"ref-jrv20107-51","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/sj.ijo.0801814","article-title":"The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia.","volume":"25","author":"Muls","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref-jrv20107-52","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity.","volume":"1","author":"Munro","year":"1968","journal-title":"BMJ"},{"key":"ref-jrv20107-53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1212\/01.WNL.0000042092.20411.5B","article-title":"Use of ephedra-containing products and risk for hemorrhagic stroke.","volume":"60","author":"Morgenstern","year":"2003","journal-title":"Neurology"},{"key":"ref-jrv20107-14","article-title":">Stata [computer program].","volume-title":"Release 7.0","author":"Not Available","year":"2001"},{"key":"ref-jrv20107-15","article-title":"StatXact 4 [computer program].","volume-title":"Version 4.0","author":"Not Available","year":"2000"},{"key":"ref-jrv20107-4","unstructured":"Public Citizen. Public Citizen Calls On FDA To Ban Dietary Supplements Containing Ephedra. September5, 2001. Available at: http:\/\/www.citizen.org\/pressroom\/release.cfm?ID=654. Accessibility verified February 17, 2003."},{"key":"ref-jrv20107-6","unstructured":"Department of Health and Human Services. HHS announces plans to study ephedra.HHS News. June14, 2002. Available at: http:\/\/www.hhs.gov\/news\/press\/2002pres\/20020614.html. Accessibility verified February 17, 2003."},{"key":"ref-jrv20107-54","unstructured":"BentS, TiedtTN, OddenMC, ShlipakMG. The relative safety of ephedra compared with other herbal products. Available at: http:\/\/www.acponline.org\/journals\/annals\/ephedra.htm?hp. Accessibility verified February 17, 2003. 12639079"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/196247\/jrv20107_1537_1545_1683230142.7252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T16:32:00Z","timestamp":1683217920000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/196247"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2003,3,26]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,3,26]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.289.12.1537","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3,26]]}}}